GARDP Request for Proposal Zoli POP PK modeling
Closing date: 25.08.2023
GARDP has entered in collaboration agreement with Innoviva Specialty Therapeutics (IST), formerly known as Entasis therapeutics for the development of Zoliflodacin. Zoliflodacin (ETX0914) is a new promising option to address the risk posed by drug[1]resistant gonorrhoea. The drug belongs to a new class of antibiotics with a novel mode of action that inhibits bacterial deoxyribonucleic acid (DNA) replication and demonstrated in vitro activity against drug resistant strains of NG. It offers many of the preferred characteristics for gonorrhoea therapy, including single dose oral therapy, low rate of side effects. It is currently the only novel drug targeting exclusively gonorrhoea, in late-stage development / pre-introduction phase in the world. The purpose of this RFP is to find a Contract Research Organization (CRO) that can provide pharmacometrics support for Zoliflodacin new drug approval. The overarching goal of this project is to select a safe and efficacious dose of Zoliflodacin as supportive evidence to the Phase 3 trial results.
If you are interested to receive complete documentation of this RFP, please send a request to: RFP_Procurement@gardp.org.
Closing date: August 25th 2023